FindTrial
Sign In

MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Complicated Intra-abdominal InfectionComplicated Urinary Tract InfectionIntra-abdominal InfectionPyelonephritisUncomplicated PyelonephritisUrinary Tract Infection (UTI)

Phase 3

Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
CompletedNCT02728089
Merck Sharp & Dohme LLCComplicated Urinary Tract Infection, Pyelonephritis, Uncomplicated Pyelonephritis +1
Start: 2016-04-14End: 2017-09-05Updated: 2019-02-05
Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
CompletedNCT02739997
Merck Sharp & Dohme LLCComplicated Intra-abdominal Infection, Intra-abdominal Infection
Start: 2016-04-08End: 2017-07-28Updated: 2018-08-09

Related Papers

Pooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections.
2025-09-061 citations
The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections
Journal of Infection and Chemotherapy2018-12-0622 citations